Product Description: IBMX (3-Isobutyl-1-methylxanthine) (GMP) is IBMX (HY-12318) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor[1][2][3][4][5].
Applications: COVID-19-immunoregulation
Formula: C10H14N4O2
References: [1]Tio M, et al. Roles of db-cAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells. PLoS One. 2010 Feb 24;5(2):e9398./[2]Kim SP, et al. Transcriptional activation of peroxisome proliferator-activated receptor-gamma requires activation of both protein kinase A and Akt during adipocyte differentiation. Biochem Biophys Res Commun. 2010 Aug 13;399(1):55-9./[3]Lange A, et al. Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro. Lung Cancer. 2011 Nov;74(2):178-87./[4]Elks ML, Manganiello VC. A role for soluble cAMP phosphodiesterases in differentiation of 3T3-L1 adipocytes. J Cell Physiol. 1985 Aug;124(2):191-8./[5]Ning H, et al. Insulin growth factor signaling mediates neuron-like differentiation of adipose-tissue-derived stem cells. Differentiation. 2008 May;76(5):488-94.
CAS Number: 28822-58-4
Molecular Weight: 222.24
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Phosphodiesterase (PDE)
English
Deutsch
